MedTrace Logo

A Comparison of Two Standard Therapies in the Management of Dementia With Agitation

NCT00208819 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2013-11-13

No results posted yet for this study

Summary

The purpose of this study is to determine whether an antipsychotic medication alone or an antipsychotic medication in combination with divalproex is the most effective and safest way to treat agitation in elderly patients with dementia.

Conditions

  • Senile Dementia, Alzheimer Type
  • Dementia, Alzheimer Type
  • Alzheimer Disease
  • Dementia

Interventions

DRUG

risperidone

DRUG

quetiapine

DRUG

olanzapine

DRUG

divalproex

Sponsors & Collaborators

  • Abbott

    collaborator INDUSTRY

  • Emory University

    lead OTHER

Principal Investigators

  • Larry E. Tune, MD, MAS · Emory University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-09-30
Completion
2007-07-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00208819 on ClinicalTrials.gov